Sugi Predict

Sugi Predict / Compounds / SCHEMBL4899387

SCHEMBL4899387

SCHEMBL4899387

Cc1cc(C(F)(F)F)c2c(N)c(C(=O)O)sc2n1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.64
▸ MAPT P10636 4/20 0.64
▸ SMN1; SMN2 Q16637 2/20 0.64
▸ CASP1 P29466 2/20 0.64
▸ CASP7 P55210 2/20 0.64
▸ NPC1 O15118 1/20 0.64
▸ USP2 O75604 1/20 0.64
▸ RAB9A P51151 1/20 0.64
▸ NPSR1 Q6W5P4 1/20 0.64
▸ LMNA P02545 1/20 0.62
▸ KDM4E B2RXH2 6/20 0.53
▸ LIMK1 P53667 4/20 0.53
▸ HPGD P15428 3/20 0.53
▸ IKBKB O14920 2/20 0.53
▸ CHUK O15111 1/20 0.53
▸ PRKACA P17612 1/20 0.53
▸ PRKACG P22612 1/20 0.53
▸ PRKACB P22694 1/20 0.53
▸ BTK Q06187 1/20 0.53
▸ HTT P42858 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30968413 1.00 ALDH1A1 (0.64) ALDH1A1MAPTSMN1; SMN2CASP1CASP7
SCHEMBL463170 0.92 LMNA (0.58) ALDH1A1MAPTSMN1; SMN2CASP1CASP7
SCHEMBL4898042 0.84 KDM4E (0.72) ALDH1A1MAPTSMN1; SMN2CASP1CASP7
SCHEMBL4892272 0.82 LMNA (0.73) ALDH1A1MAPTSMN1; SMN2CASP1CASP7
SCHEMBL30968548 0.81 KDM4E (0.78) ALDH1A1MAPTSMN1; SMN2CASP1CASP7
SCHEMBL14954934 0.81 KDM4E (0.78) ALDH1A1MAPTSMN1; SMN2CASP1CASP7
SCHEMBL4896350 0.81 CHRM4 (0.75) ALDH1A1MAPTSMN1; SMN2CASP1CASP7
SCHEMBL27663442 0.80 IKBKB (0.59) ALDH1A1MAPTSMN1; SMN2CASP1CASP7
SCHEMBL4896437 0.80 MAPT (0.62) ALDH1A1MAPTSMN1; SMN2CASP1CASP7
SCHEMBL10134575 0.80 RAB9A (0.74) ALDH1A1MAPTSMN1; SMN2CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 — — US claimed
CN-101128470-A Novel compounds ASTRAZENECA AB (SE) 2008-02-20 — — CN claimed
EP-1833834-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2007-09-19 — — EP claimed
WO-2006068618-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2006-06-29 — — WO claimed
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2024-12-10 — — US disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 — — US disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 — — US disclosed
EP-3414252-B1 THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO HEALTH INC (US) 2022-07-06 — — EP disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 — — US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 — — US disclosed
EP-3833661-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Valo Early Discovery, Inc. (US) 2021-06-16 — — EP disclosed
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-02-09 — — US disclosed
US-9301949-B2 Thienopyridine derivatives for the treatment and prevention of dengue virus infections SIGA TECHNOLOGIES, INC. (US) 2016-04-05 — — US disclosed
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. (US) 2013-05-23 — — US disclosed
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 — — US disclosed
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 — — US disclosed
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 — — US disclosed
CN-101128470-A Novel compounds ASTRAZENECA AB (SE) 2008-02-20 — — CN disclosed
EP-1833834-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2007-09-19 — — EP disclosed
WO-2006068618-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2006-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 ALDH1A1 2323/4885MAPT 2364/4885SMN1; SMN2 3449/4885
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 ALDH1A1 2167/4885MAPT 2661/4885SMN1; SMN2 2918/4885
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 ALDH1A1 2167/4885MAPT 2661/4885SMN1; SMN2 2918/4885
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections TTPA, TPMT, SLC19A2 ALDH1A1 1400/4885MAPT 85/4885SMN1; SMN2 1076/4885
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 ALDH1A1 2167/4885MAPT 2661/4885SMN1; SMN2 2918/4885
US-20080306107-A1 Compounds FURIN, PCSK9, SLC10A1 ALDH1A1 609/4885MAPT 1464/4885SMN1; SMN2 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.